Be One in a Million Hearts. Join the conversation, get connected and learn more.

CV Risk for Diabetics taking Olmesartan

FDA Drug Safety Communication: FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required

This information is in follow-up to the FDA Drug Safety Communication1: Safety Review Update of Benicar (olmesartan) and cardiovascular events2.

View and print full Drug Safety Communication (PDF – 146KB)

Safety Announcement

[6-24-2014] The U.S. Food and Drug Administration (FDA) has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication olmesartan in diabetic patients.  As a result, our recommendations for use of olmesartan (Benicar, Benicar HCT, Azor, Tribenzor, and generics) will remain the same, but we will require information about some of the studies to be included in the drug labels.  Patients should discuss any questions they have with their health care professionals.

It is important to take olmesartan and other blood pressure medicines because uncontrolled high blood pressure increases the risks of cardiovascular problems such as heart disease and stroke, as well as kidney failure and other health problems.  Do not stop taking olmesartan or any blood pressure medication without first discussing it with your health care professional.

This safety review was prompted by the results of the ROADMAP trial. The ROADMAP (Randomized Olmesartan and Diabetes Microalbuminuria Prevention)1 clinical trial examined the effects of olmesartan in patients with type 2 diabetes, to see whether olmesartan could delay kidney damage. There was an unexpected finding of increased risk of cardiovascular death in the olmesartan group compared to the group taking a placebo, or sugar pill. However, the risk of non-fatal heart attack was lower in the olmesartan-treated patients.

To evaluate these findings, we reviewed additional studies, including a large study in Medicare patients. Overall, we have determined that these studies do not clearly show an increased cardiovascular risk. Thus, the collective evidence available at this time does not support changing our recommendations for olmesartan use and does not support recommending that its use be avoided in patients with diabetes.

Olmesartan is a type of blood pressure medicine called an angiotensin receptor blocker, or ARB.  In 2013, there were approximately 1.8 million patients who received a dispensed prescription for olmesartan-containing products from U.S. outpatient retail pharmacies.2

FDA posted two previous Drug Safety Communications (DSCs) on this issue.  The first, in June 2010, described the ongoing review of olmesartan and cardiovascular events4The second was a DSC update in April 20115.

We urge health care professionals and patients to report side effects involving olmesartan to the FDA MedWatch program, using the “Contact FDA” link.

This information from: http://www.fda.gov/Drugs/DrugSafety/ucm402323.htm (Accessed 6-25-2014)

Categorised in: Provider, Science/ Evidence Update

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Million Hearts® Delaware Founding Partners

Christiana Care Health System
Delaware Center for Health Promotion at Delaware State University
Delaware Academy of Family Physicians
Delaware Academy of Medicine
Delaware Chapters of the American Heart Association
Delaware Greenways
Delaware Healthcare Association
Medical Society of Delaware
Nemours Alfred I. duPont Hospital for Children
Quality Insights of Delaware
American College of Cardiology - Delaware
State of Delaware, Division of Public Health

Million Hearts DE website is sponsored by the Delaware Academy of Family Physicians.

Delaware Academy of Family Physicias logo

Million Hearts DE is supported by a grant from Christiana Care Health System.

Christiana Care Health System
The Million Hearts® word and logo marks, and the Be One in a Million Hearts®slogan and logo marks and associated trade dress are owned by the U.S. Department of Health and Human Services (HHS) Use of these marks does not imply endorsement by HHS. Use of the Marks also does not necessarily imply that the materials have been reviewed or approved by HHS.
%d bloggers like this: